Table 3.
Individual clinical and demographical characteristics of MS patients followed by a minimum of 2 years after AHSCT
| Patient and year of AHSCT | Gender | Age at AHSCT | MS duration (year) | Relapses before AHSCT | Baseline EDSS | Evolution time after AHSCT (year) | Current EDSS | Previous therapy | |
|---|---|---|---|---|---|---|---|---|---|
| 2 years | 1 year | ||||||||
| Relapsing-remitting MS patients (n = 22) | |||||||||
| #1, 1999 | M | 44 | 13.1 | 2 | 1 | 6.50 | 16.83 | 6.0 | IFN |
| #2, 2004 | F | 37 | 13.4 | 2 | 1 | 4.00 | 10.83 | 3.5 | IFN, MTX, |
| #3, 2005 | F | 30 | 6.4 | 1 | 3 | 5.00 | 10.75 | 2.0 | IFN, GA, AZA, MTX |
| #4, 2005 | F | 36 | 3.1 | 1 | 2 | 5.00 | 10.08 | 4.0 | IFN |
| #5, 2007 | M | 27 | 7.6 | 1 | 1 | 3.00 | 7.92 | 2.5 | IFN, MTX |
| #6, 2008 | F | 33 | 11.9 | 0 | 1 | 6.00 | 7.67 | 5.5 | GA, IFN, MTX, IFN |
| #7, 2008 | F | 26 | 9.4 | 2 | 5 | 5.50 | 7.08 | 2.0 | IFN, MTX, IFN, NTZ, GA |
| #8, 2009 | F | 43 | 11.9 | 1 | 2 | 5.00 | 6.92 | 4.0 | IFN, Cy |
| #9, 2009 | F | 44 | 9.0 | 0 | 1 | 5.50 | 6.75 | 5.5 | IFN, MTX |
| #10, 2009 | F | 32 | 11.4 | 1 | 2 | 3.00 | 6.58 | 3.0 | IFN, GA, NTZ |
| #11, 2010 | M | 47 | 7.3 | 0 | 3 | 4.50 | 5.42 | 3.5 | IFN, GA, NTZ, Cy |
| #12, 2010 | F | 45 | 13.1 | 2 | 1 | 4.50 | 5.42 | 3.5 | IFN, AZA, DCZ, Cy, GA, IFN |
| #13, 2011 | F | 30 | 6.1 | 0 | 1 | 4.00 | 4.92 | 3.5 | IFN, MTX, NTZ |
| #14, 2012 | M | 12 | 2.8 | 2 | 2 | 6.00 | 3.83 | 1.0 | IFN, GA, Cy |
| #15, 2012 | F | 46 | 7.5 | 2 | 2 | 3.50 | 3.33 | 3.5 | IFN, NTZ, FGM |
| #16, 2013 | F | 34 | 5.1 | 0 | 1 | 5.50 | 2.58 | 4.0 | IFN, NTZ, RTX |
| #17, 2013 | M | 37 | 13.2 | 1 | 1 | 4.00 | 2.58 | 4.0 | IFN, MTX, IFN, NTZ |
| #18, 2013 | M | 35 | 9.9 | 1 | 1 | 6.50 | 2.42 | 3.5 | IFN, NTZ |
| #19, 2013 | F | 41 | 7.3 | 0 | 1 | 4.00 | 2.17 | 2.5 | Cy, IFN |
| #20, 2013 | F | 20 | 1.2 | 2 | 2 | 6.00 | 2.08 | 3.5 | IFN, NTZ |
| #21, 2013 | F | 39 | 9.6 | 0 | 3 | 6.00 | 2.00 | 4.0 | IFN, NTZ, FGM |
| #22, 2013 | F | 33 | 6.2 | 0 | 1 | 9.00 | 2.00 | 1.5 | IFN, NTZ |
| Mean (SD)a | 72.7% | 35.0 (8.7) | 8.4 (3.6) | 1.0 (0.8) | 1.7 (1.0) | 5.0 (1.3) | 5.9 (3.7) | 3.4 (1.2) | RRMS |
| Secondary progressive MS patients (n = 9) | |||||||||
| #23, 2001 | F | 26 | 4.64 | 3 | 6 | 6.50 | 13.50 | 10.00 | IFN, AZA |
| #24, 2002 | F | 42 | 12.12 | 0 | 1 | 4.50 | 13.17 | 5.50 | IFN |
| #25, 2004 | F | 42 | 3.76 | 0 | 1 | 6.50 | 11.67 | 8.00 | IFN, MTX |
| #26, 2005 | F | 32 | 7.98 | 0 | 0 | 6.50 | 10.67 | 8.00 | IFN, AZA, MTX |
| #27, 2005 | F | 45 | 8.60 | 1 | 1 | 6.50 | 10.25 | 6.50 | IFN, MTX Cy, AZA |
| #28, 2007 | M | 47 | 14.48 | 0 | 1 | 6.00 | 8.25 | 6.50 | IFN, AZA, MTX, IFN |
| #29, 2008 | F | 34 | 15.09 | 0 | 1 | 6.50 | 7.83 | 8.50 | IFN, MTX |
| #30, 2008 | M | 34 | 5.25 | 0 | 1 | 6.00 | 7.00 | 8.00 | IFN, MTX |
| #31, 2011 | M | 22 | 2.51 | 2 | 0 | 6.00 | 4.08 | 4.00 | IFN |
| Mean (SD)a | 66.7% | 36.0 (8.6) | 8.2 (4.6) | 0.6 (1.1) | 1.3 (1.8) | 6.1 (0.6) | 9.6 (3.0) | 7.2 (1.7) | SPMS |
| Total series (n = 31) | |||||||||
| Mean (SD)a | 71.0% | 35.7 (3.8) | 8.4 (3.8) | 0.9 (0.9) | 1.6 (1.2) | 5.3 (1.2) | 8.4 (3.8) | 4.5 (2.2) | |
IFN interferon beta, MTX mitoxantrone, GA glatiramer acetate, AZA azathioprine, NTZ natalizumab, Cy ciclosphosphamide, DCZ daclizumab, FGM fingolimod, RTX rituximab
aMean and standard deviation except column of gender that represents the percentage of females